Foreign Affairs

Donald Trump’s 200% tariffs on pharma: Why India’s generic medicines could still remain competitive

· 22 July 2026 · 2 min read
Donald Trump’s 200% tariffs on pharma: Why India’s generic medicines could still remain competitive

The Times of India has reported a new India-focused foreign affairs development: “Donald Trump’s 200% tariffs on pharma: Why India’s generic medicines could still remain competitive.” The publisher's feed describes the story as follows: <![CDATA[US President Donald Trump on Tuesday announced the final stage of his pharmaceutical tariff plan, under which imported generic medicines will continue to enter the US without duties until August 1, 2028. Intellectual Janata Party includes this item for

Original reporting by The Times of IndiaRead the full story

Intellectual Janata displays only original summaries of externally sourced news and links readers to the original publisher.

#foreign-affairs#india

Related reading

IJP
News Brief
Foreign secretary Vikram Misri flags tariff move in talks with US undersecretary
Foreign Affairs·The Economic Times·25 Sep 2026

Foreign secretary Vikram Misri flags tariff move in talks with US undersecretary

Read full story →
IJP
News Brief
India and the plausible multilateralism of BRICS
Foreign Affairs·The Hindu·25 Sep 2026

India and the plausible multilateralism of BRICS

Read full story →
IJP
News Brief
CEA flags US friction, energy shocks, and missing AI play as India’s key near-term risks
Foreign Affairs·Mint·25 Sep 2026

CEA flags US friction, energy shocks, and missing AI play as India’s key near-term risks

Read full story →
IJP
News Brief
India, 17 others reserve rights to join Russia’s CBAM dispute with EU as third party at WTO
Foreign Affairs·The Economic Times·25 Sep 2026

India, 17 others reserve rights to join Russia’s CBAM dispute with EU as third party at WTO

Read full story →